Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

to those described in our annual report on Form 10-K for the year ended December 31, 2009 and 10-Q filings for the quarters ended March 31, 2010, June 30, 2010 and September 30, 2010 filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 15, 2014 The Cadence Fitness & Health Center ... the Medical Fitness Association, a non-profit organization assisting medically ... potential. The Cadence Fitness & Health Center is the ... second in the Chicagoland area. "The certification ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:4/24/2014)... better understanding of drug interactions, which are a major ... two or more medications are taken at the same ... the other. Similarly, one drug may magnify the ... major cause of illness and hospitalization. However, there ... drug studies in humans. Limits come in part ...
(Date:4/24/2014)... lenses coated with an antimicrobial peptide could help to lower ... Optometry and Vision Science , official journal ... journal is published by Lippincott Williams & Wilkins , ... in animals and now humans support the biocompatibility and safety ... the new research by Debarun Dutta, B.Optom, of The University ...
(Date:4/24/2014)... April 28, the Center for BrainHealth will bring ... most pressing brain-related challenges at its inaugural Brain ... and Regeneration." Featured speakers will include Dr. Sandra ... Center for BrainHealth, U.S. Senator Chuck Grassley (R-IA), ... Deputy Assistant Secretary for Policy and Early Learning, ...
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
Breaking Medicine News(10 mins):Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2
... NEW YORK, May 12 portionpals(R), an innovative,weight-loss tool ... million sales mark,this past Saturday, May 10th, in less ... the "diet" alternative among consumers,looking for a healthy way ... is,gaining market share in a multi-billion dollar industry with ...
... serious, but genetics could bring screening test or treatment , , ... COMT, already known for its role in schizophrenia, also plays ... preeclampsia, a new study finds. , Although the current study ... the findings could be used as a test to identify ...
... MEDX ) announced today its financial results for the quarter ... or $1.19 per share, from Medarex,s,sale of 2.5 million shares ... the quarter ended March 31, 2008, was $103.3 million, or,$0.81 ... million, or $0.88,per share for the same period in 2007. ...
... DUBLIN, Ohio, May 12 On May 30, 2008, ... Chicago, New York,Philadelphia, Cleveland, Madison, Atlanta, Seattle, Dearborn, and ... Abigail Alliance, A Right,To Live, and the Sarcoma Foundation ... out and attend a protest., 1 in 6 ...
... MedCath Corporation,(Nasdaq: MDTH ), a health ... predominantly the diagnosis and treatment of cardiovascular,disease, today ... currently Interim Chief Financial Officer, has been named,Senior ... his new role, Art will continue to oversee ...
... YORK, May 12 InfuSystem Holdings, Inc.,(OTC Bulletin ... infusion pumps and associated clinical services, today announced,financial ... first quarter of,2008., Mr. Steve Watkins, chief ... of our first full quarter of operations as ...
Cached Medicine News:Health News:Diet Industry Newcomer Hits the 1 Million Unit Mark 2Health News:Gene May Be Key to Pregnancy Complication 2Health News:Gene May Be Key to Pregnancy Complication 3Health News:Medarex Announces 2008 First Quarter Financial Results 2Health News:Medarex Announces 2008 First Quarter Financial Results 3Health News:Medarex Announces 2008 First Quarter Financial Results 4Health News:Medarex Announces 2008 First Quarter Financial Results 5Health News:Medarex Announces 2008 First Quarter Financial Results 6Health News:Medarex Announces 2008 First Quarter Financial Results 7Health News:Medarex Announces 2008 First Quarter Financial Results 8Health News:FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy 2Health News:FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy 3Health News:MedCath Names Parker to New Finance Post 2Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 2Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 3Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 4Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 5Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 6Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 7Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 8Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 9
Midstream Catch Kits...
... a handheld, noninvasive ultrasound instrument that measures ... so any staff member can scan patients ... from exams and print BVI 6100 exam ... log on to ScanPoint®, Diagnostic Ultrasound's innovative ...
... The Mobile BladderScan® BVI 6400 calculates ... ultrasound technology. V-MODE® ultrasound is accurate, ... seconds, the BladderScan® measures ultrasonic reflections ... planes, creates a 3-dimensional image of ...
... EXP Injectable Bulking Agent is ... suspended in a water-based carrier ... Agent is indicated for the ... stress urinary incontinence due to ...
Medicine Products: